drugset / Trial / NCT00910247

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247

Phase 3 Completed 274 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a long term, open-label, safety extension study in subjects with partial onset seizures.

Timeline

Start
2009-08
Primary completion
2017-04-15
Completion
2017-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 800 mg
Subject Eslicarbazepine acetate Unknown 2400 mg

Indications